BR112015012730A2 - compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos - Google Patents
compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicosInfo
- Publication number
- BR112015012730A2 BR112015012730A2 BR112015012730A BR112015012730A BR112015012730A2 BR 112015012730 A2 BR112015012730 A2 BR 112015012730A2 BR 112015012730 A BR112015012730 A BR 112015012730A BR 112015012730 A BR112015012730 A BR 112015012730A BR 112015012730 A2 BR112015012730 A2 BR 112015012730A2
- Authority
- BR
- Brazil
- Prior art keywords
- beta2
- compounds
- agonist activity
- adrenergic receptor
- muscarinic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
resumo compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos a presente invenção se refere a compostos que atuam tanto como antagonistas de receptores muscarínicos quanto como agonistas de receptores beta2-adrenérgicos, aos processos para sua preparação, às composições que os compreendem, aos usos terapêuticos e às combinações com outros ingredientes farmaceuticamente ativos. 1/1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195891.2 | 2012-12-06 | ||
| EP12195891 | 2012-12-06 | ||
| PCT/EP2013/075661 WO2014086924A1 (en) | 2012-12-06 | 2013-12-05 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015012730A2 true BR112015012730A2 (pt) | 2017-07-11 |
| BR112015012730B1 BR112015012730B1 (pt) | 2022-07-05 |
Family
ID=47323975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015012730-4A BR112015012730B1 (pt) | 2012-12-06 | 2013-12-05 | Composto, composição farmaceutica, dispositivo, uso de um composto e combinação |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8987299B2 (pt) |
| EP (2) | EP2928889B1 (pt) |
| JP (1) | JP6421989B2 (pt) |
| KR (2) | KR102156443B1 (pt) |
| CN (1) | CN104822678B (pt) |
| AR (1) | AR093825A1 (pt) |
| AU (1) | AU2013354043C1 (pt) |
| BR (1) | BR112015012730B1 (pt) |
| CA (1) | CA2893626C (pt) |
| CL (1) | CL2015001483A1 (pt) |
| CO (1) | CO7400870A2 (pt) |
| CY (2) | CY1120159T1 (pt) |
| DK (2) | DK2928889T3 (pt) |
| EA (1) | EA030552B1 (pt) |
| ES (2) | ES2670686T3 (pt) |
| GE (1) | GEP20186839B (pt) |
| HK (1) | HK1212989A1 (pt) |
| HR (2) | HRP20180915T1 (pt) |
| HU (2) | HUE037944T2 (pt) |
| IL (1) | IL239182B (pt) |
| LT (2) | LT3345904T (pt) |
| MA (1) | MA38147B1 (pt) |
| MX (1) | MX369311B (pt) |
| NZ (1) | NZ708738A (pt) |
| PE (1) | PE20151216A1 (pt) |
| PH (1) | PH12015501247A1 (pt) |
| PL (2) | PL2928889T3 (pt) |
| PT (2) | PT2928889T (pt) |
| RS (2) | RS57232B1 (pt) |
| SA (1) | SA515360514B1 (pt) |
| SG (2) | SG10201704032RA (pt) |
| SI (2) | SI2928889T1 (pt) |
| TN (1) | TN2015000244A1 (pt) |
| TR (1) | TR201808698T4 (pt) |
| TW (1) | TWI637954B (pt) |
| UA (1) | UA118181C2 (pt) |
| WO (1) | WO2014086924A1 (pt) |
| ZA (1) | ZA201503965B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| HUE037944T2 (hu) * | 2012-12-06 | 2018-09-28 | Chiesi Farm Spa | Muszkarin receptor antagonista és béta2 adrenerg receptor agonista akitvitással rendelkezõ vegyületek |
| TW201427977A (zh) * | 2012-12-06 | 2014-07-16 | Chiesi Farma Spa | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體致效劑活性之化合物 |
| BR112015013628A2 (pt) | 2012-12-18 | 2017-07-11 | Almirall Sa | derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TWI703138B (zh) * | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AR104828A1 (es) | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
| ES2891073T3 (es) * | 2015-11-16 | 2022-01-26 | Chiesi Farm Spa | Un procedimiento para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticoesteroide y un beta-adrenérgico |
| EP3383867B1 (en) | 2015-12-03 | 2021-04-14 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| EP3484879B1 (en) | 2016-07-13 | 2020-12-30 | Chiesi Farmaceutici S.p.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CA2994290C (en) | 2017-11-06 | 2024-01-23 | Entech Solution As | Method and stimulation sleeve for well completion in a subterranean wellbore |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2222128A (en) | 1937-01-29 | 1940-11-19 | Pure Oil Co | Preparation and separation of aromatic hydrocarbons |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| CA2499314C (en) | 2002-10-11 | 2010-08-24 | Pfizer Inc. | Indole derivatives as beta-2 agonists |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| JP4851937B2 (ja) | 2003-11-21 | 2012-01-11 | セラヴァンス， インコーポレーテッド | β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物 |
| CA2553293C (en) | 2004-01-22 | 2010-12-14 | Pfizer Inc. | Sulfonamide derivatives for the treatment of diseases |
| WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
| BRPI0507877A (pt) | 2004-03-23 | 2007-07-24 | Pfizer | derivados de formamida, composição farmacêutica, uso dos mesmos e combinação |
| US7538141B2 (en) | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| US7528253B2 (en) | 2004-08-16 | 2009-05-05 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| WO2006023460A2 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| FR2898640B1 (fr) | 2006-03-20 | 2008-04-25 | Siemens Vdo Automotive Sas | Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne |
| EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| PL3210981T3 (pl) | 2009-04-23 | 2019-06-28 | Theravance Respiratory Company, Llc | Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego |
| EP2426121A4 (en) * | 2009-04-30 | 2012-10-31 | Teijin Pharma Ltd | QUARTER AMMONIUM SALT CONNECTION |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| KR101906630B1 (ko) | 2011-06-10 | 2018-10-10 | 키에시 파르마슈티시 엣스. 피. 에이. | 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 |
| PT2718280E (pt) | 2011-06-10 | 2015-11-25 | Chiesi Farma Spa | Compostos possuindo uma atividade antagonista de um recetor muscarínico e agonista de um recetor beta2 adrenérgico |
| HUE037944T2 (hu) * | 2012-12-06 | 2018-09-28 | Chiesi Farm Spa | Muszkarin receptor antagonista és béta2 adrenerg receptor agonista akitvitással rendelkezõ vegyületek |
| TW201427977A (zh) * | 2012-12-06 | 2014-07-16 | Chiesi Farma Spa | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體致效劑活性之化合物 |
-
2013
- 2013-12-05 HU HUE13811827A patent/HUE037944T2/hu unknown
- 2013-12-05 LT LTEP18156043.4T patent/LT3345904T/lt unknown
- 2013-12-05 MX MX2015006788A patent/MX369311B/es active IP Right Grant
- 2013-12-05 TW TW102144561A patent/TWI637954B/zh not_active IP Right Cessation
- 2013-12-05 RS RS20180529A patent/RS57232B1/sr unknown
- 2013-12-05 GE GEAP201313845A patent/GEP20186839B/en unknown
- 2013-12-05 LT LTEP13811827.8T patent/LT2928889T/lt unknown
- 2013-12-05 PL PL13811827T patent/PL2928889T3/pl unknown
- 2013-12-05 EA EA201590873A patent/EA030552B1/ru unknown
- 2013-12-05 ES ES13811827.8T patent/ES2670686T3/es active Active
- 2013-12-05 KR KR1020157014956A patent/KR102156443B1/ko active IP Right Grant
- 2013-12-05 DK DK13811827.8T patent/DK2928889T3/en active
- 2013-12-05 HU HUE18156043A patent/HUE051394T2/hu unknown
- 2013-12-05 CA CA2893626A patent/CA2893626C/en active Active
- 2013-12-05 AR ARP130104529A patent/AR093825A1/es unknown
- 2013-12-05 UA UAA201505478A patent/UA118181C2/uk unknown
- 2013-12-05 PT PT138118278T patent/PT2928889T/pt unknown
- 2013-12-05 PL PL18156043T patent/PL3345904T3/pl unknown
- 2013-12-05 MA MA38147A patent/MA38147B1/fr unknown
- 2013-12-05 DK DK18156043.4T patent/DK3345904T3/da active
- 2013-12-05 NZ NZ708738A patent/NZ708738A/en not_active IP Right Cessation
- 2013-12-05 JP JP2015546012A patent/JP6421989B2/ja active Active
- 2013-12-05 CN CN201380063365.2A patent/CN104822678B/zh active Active
- 2013-12-05 SG SG10201704032RA patent/SG10201704032RA/en unknown
- 2013-12-05 SI SI201330994T patent/SI2928889T1/en unknown
- 2013-12-05 ES ES18156043T patent/ES2816210T3/es active Active
- 2013-12-05 WO PCT/EP2013/075661 patent/WO2014086924A1/en active Application Filing
- 2013-12-05 EP EP13811827.8A patent/EP2928889B1/en active Active
- 2013-12-05 SI SI201331764T patent/SI3345904T1/sl unknown
- 2013-12-05 TR TR2018/08698T patent/TR201808698T4/tr unknown
- 2013-12-05 RS RS20201150A patent/RS60864B1/sr unknown
- 2013-12-05 EP EP18156043.4A patent/EP3345904B1/en active Active
- 2013-12-05 SG SG11201504318UA patent/SG11201504318UA/en unknown
- 2013-12-05 PE PE2015000738A patent/PE20151216A1/es active IP Right Grant
- 2013-12-05 AU AU2013354043A patent/AU2013354043C1/en active Active
- 2013-12-05 KR KR1020207006181A patent/KR102240459B1/ko active IP Right Grant
- 2013-12-05 PT PT181560434T patent/PT3345904T/pt unknown
- 2013-12-05 BR BR112015012730-4A patent/BR112015012730B1/pt active IP Right Grant
- 2013-12-06 US US14/098,735 patent/US8987299B2/en active Active
-
2015
- 2015-01-23 US US14/603,926 patent/US9371318B2/en active Active
- 2015-06-02 CL CL2015001483A patent/CL2015001483A1/es unknown
- 2015-06-03 TN TNP2015000244A patent/TN2015000244A1/fr unknown
- 2015-06-03 PH PH12015501247A patent/PH12015501247A1/en unknown
- 2015-06-03 SA SA515360514A patent/SA515360514B1/ar unknown
- 2015-06-03 ZA ZA2015/03965A patent/ZA201503965B/en unknown
- 2015-06-03 IL IL239182A patent/IL239182B/en active IP Right Grant
- 2015-06-03 CO CO15127118A patent/CO7400870A2/es unknown
-
2016
- 2016-01-29 HK HK16101057.0A patent/HK1212989A1/zh unknown
-
2018
- 2018-05-03 CY CY20181100469T patent/CY1120159T1/el unknown
- 2018-06-13 HR HRP20180915TT patent/HRP20180915T1/hr unknown
-
2020
- 2020-09-09 HR HRP20201435TT patent/HRP20201435T1/hr unknown
- 2020-09-28 CY CY20201100912T patent/CY1123365T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015012746A2 (pt) | compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos | |
| BR112015012730A2 (pt) | compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos | |
| SG195375A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| CR20140182A (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos b2 y como antagonistas muscarínicos m3 | |
| CL2013000732A1 (es) | Compuestos derivados de analogos de buprenorfina, con actividad como agonistas y/o antagonistas de receptores opioides; composicion que los comprende; su metodo de preparacion; y su uso para el tratamiento o prevencion del dolor o constipacion. | |
| ECSP14013340A (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenérgicos ?2 y como antagonistas muscarínicos m3 | |
| ECSP12012213A (es) | Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos ? 2 y como antagonistas muscarinicos m3 | |
| NI201500080A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3. | |
| CR20150322A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenérgicos y como antagonistas muscarínicos m3 | |
| UY32734A (es) | Compuestos agonistas del receptor esfingosina 1-fosfato | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| GT201300304A (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| BR112017023484A2 (pt) | compostos tendo atividade de antagonista de receptor muscarínico e agonista de receptor beta2 adrenérgico | |
| BR112013025682A2 (pt) | Compostos, composição farmacêutica, uso de um composto, combinação e dispositivo | |
| BR112018075817A2 (pt) | composto de fórmula (i), medicamento e composição farmacêutica | |
| TN2013000429A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| UA109581C2 (uk) | Сполуки з активністю антагоністів мускаринових рецепторів і агоністів адренергічного рецептора бета2 | |
| ECSP15026152A (es) | Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas beta2 adrenérgicos y como antagonistas muscarínicos m3 | |
| BR112015015491A2 (pt) | compostos (tieno[2,3-b][1,5] benzoxazepin-4-il) piperazin-1-ila com atividade dual como agonistas inversos h1/antagonistas 5-ht2a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 453/02 Ipc: C07D 453/02 (2006.01), A61K 31/439 (2006.01), A61K |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2013, OBSERVADAS AS CONDICOES LEGAIS |